Stugeron
In brief
- In our pharmacy, you can buy stugeron without a prescription, with delivery across Australia and discreet, anonymous packaging.
- Stugeron (cinnarizine) is used for motion sickness, vertigo and some cerebral/peripheral circulatory vestibular disorders; it acts mainly as a calcium‑channel blocker on the vestibular system, reducing vestibular excitation and improving blood flow.
- Usual dosage: Adults — 25 mg for motion sickness (take ~2 hours before travel, repeat every 8 hours if needed); for vertigo/vestibular disorders 25 mg three times daily (total 75 mg/day). Children 5–12 years: 12.5 mg two to three times daily; not recommended under 5 years. Dose may be reduced in the elderly or in hepatic impairment.
- Form of administration: oral tablet (25 mg most common); syrup/suspension and extended‑release forms available in some regions.
- Onset time: effects generally begin within about 1–2 hours (hence the advice to take around 2 hours before travel).
- Duration of action: typically around 8 hours, which is why dosing is commonly repeated every 8 hours for motion sickness.
- Alcohol warning: avoid alcohol — it increases drowsiness and sedation and can worsen impairment of driving or operating machinery; use caution with other CNS depressants.
- The most common side effec is drowsiness (sedation); other common effects include dry mouth, headache, mild nausea, GI upset and fatigue, and prolonged use may cause weight gain; it can worsen Parkinsonian symptoms.
- Would you like to try stugeron without a prescription?
Basic Stugeron Information
- INN (International Nonproprietary Name): Cinnarizine.
- Brand Names Available In Australia: Not registered in public formulary; international brand Stugeron (25 mg) exists in many countries but Australia shows “Not registered in public formulary” in product data.
- ATC Code: N07CA02 — other nervous system drugs; calcium channel blockers for vestibular disorders.
- Forms & Dosages: Oral tablet 25 mg most common; extended‑release formulations are rare in some markets; syrup/suspension available in select regions.
- Manufacturers In Australia: Not specified.
- Registration Status In Australia: Not on public formulary; unregistered according to provided product data.
- OTC / Rx Classification: Mostly OTC in EU and UK for motion sickness; may require prescription in some countries; Australia: not on public formulary and availability is variable.
Critical Warnings & Restrictions (Safety First For Australian Patients)
High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)
People often ask who must avoid stugeron and why.
Cinnarizine can cause sedation, confusion and extrapyramidal symptoms and may worsen Parkinsonism.
Avoid use in pregnancy and breastfeeding unless a specialist advises, as many product monographs list this as a contraindication.
Use extreme caution in the elderly, those with severe hepatic impairment, porphyria or a history of movement disorders.
- Checklist for Screening High‑Risk Features:
- Age over 65 years.
- Known Parkinson’s disease or parkinsonian features.
- Active liver disease or jaundice.
- History of porphyria or unexplained neurological signs.
- Pregnancy or breastfeeding status.
- Use of multiple CNS‑active medicines (polypharmacy).
- Contraindications:
- Allergy to cinnarizine or excipients.
- Porphyria.
- Severe hepatic impairment.
- Pregnancy and breastfeeding (avoid unless specialist advises).
- Definitions:
- Extrapyramidal: movement disorders such as tremor, rigidity, restlessness or dystonia caused by drug effects on motor pathways.
- Porphyria: a group of rare metabolic disorders affecting haem synthesis that can be triggered by some medicines.
Pharmacist or GP review is recommended before use and document allergies and current medicines in the patient file.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Many patients want to know if they can drive after taking cinnarizine.
Cinnarizine commonly causes drowsiness and may impair driving or operating machinery.
Under Australian road rules and workplace health and safety law, patients must not drive if affected by sedation or impaired reaction times.
Counsel about night shifts, heavy machinery operation and the increased risk when combined with alcohol.
Advise workers to discuss fitness for duty with their GP or occupational health provider and to obtain a WorkCover or GP note if necessary.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking cinnarizine (Stugeron)?
A: No — avoid driving or operating machinery until you know how it affects you.
If you feel drowsy do not drive; this aligns with TGA advice and workplace safety obligations.
Usage Basics
INN, Brand Names Available In Australia
The active substance is the International Nonproprietary Name cinnarizine.
Internationally the drug is widely known as Stugeron, usually as 25 mg tablets in blister packs or bulk boxes.
In Australia the product data indicates Stugeron is not registered in the public formulary and availability is variable.
- INN and Alternate Spellings:
- Cinnarizine.
- Stugeron (international brand), Cinarizina, Cinnarizin (regional spellings).
| Product | International Availability | Australian Status |
|---|---|---|
| Stugeron 25 mg tablet | Widely available in EU, UK, Canada and others | Not registered in public formulary |
| Cinnarizine generics | Available from multiple manufacturers in EU/Canada | Availability variable; check ARTG or supplier |
Legal Classification (TGA‑Approved, PBS‑Listed)
Cinnarizine is recognised internationally but in Australia it is typically not listed on the PBS and may not be registered on the ARTG as Stugeron.
If patients seek cinnarizine advise checking the ARTG and discuss options with a GP for TGA‑approved alternatives such as promethazine or hyoscine.
Confirm legality of importation before purchase and document the source and counselling in the pharmacy record.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
The most common strength worldwide is 25 mg oral tablets.
For motion sickness take 25 mg two hours before travel and repeat every eight hours if required.
For vertigo or vestibular disorders the usual adult dose is 25 mg three times daily (total 75 mg/day).
Children under five years — not recommended.
Children aged five to 12 years often use 12.5 mg two to three times daily.
| Indication | Typical Adult Dose | Paediatric Note |
|---|---|---|
| Motion Sickness | 25 mg, 2 hrs before travel, repeat q8h if needed | Not for under 5 yrs; 5–12 yrs reduced dose |
| Vertigo / Vestibular Disorder | 25 mg, three times daily (75 mg/day) | Reduce in younger children per guidance |
- Checklist For Dose Adjustments:
- Lower dose or avoid in severe hepatic impairment.
- Reduce or choose alternatives in Parkinson’s disease.
- Monitor elderly for confusion and falls.
Adjustments For Comorbidities
Reduce dose or avoid in severe hepatic impairment because cinnarizine is primarily hepatically metabolised.
Avoid in Parkinson’s disease as it may worsen parkinsonian symptoms.
Exercise caution when combining with other CNS depressants such as benzodiazepines or opioids.
Consider a pharmacy‑led medication review for patients on multiple medicines.
Q&A — “What If I Miss A Dose?”
Q: Missed dose guidance?
A: Take the missed dose when remembered unless it is close to the next dose, in which case skip it and do not double up.
For single‑dose travel use, skip a missed pre‑travel dose and take the usual dose on the next travel episode.
Interaction Chart
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Alcohol increases sedation and may worsen dizziness and fall risk when combined with cinnarizine.
Caffeine or coffee may mask some feelings of drowsiness but will not prevent movement‑related side effects such as tremor or rigidity.
In hot Australian climates dehydration and sedation together increase risk of fainting and falls.
- Immediate Food/Drink Cautions:
- Avoid alcohol during treatment.
- Maintain adequate hydration, especially in heat and after exertion.
- Avoid heavy labour or prolonged sun exposure soon after dosing.
- Heat‑Related Precautions:
- Store water and take frequent breaks in hot weather.
- Advise elderly and rural workers to plan dosing around cooler parts of the day.
Common Drug Conflicts
Cinnarizine can cause additive CNS depression with benzodiazepines, opioids and some antidepressants.
Concurrent antipsychotics increase the risk of extrapyramidal symptoms when combined with cinnarizine.
Caution with anticholinergic medicines due to cumulative side effects like dry mouth and confusion.
Hepatic metabolism involves CYP2D6; check for strong inhibitors or inducers when possible.
| Drug Class | Type Of Risk |
|---|---|
| Benzodiazepines, Opioids | Increased sedation and respiratory risk |
| Antipsychotics | Higher extrapyramidal/movement disorder risk |
| Anticholinergics | Increased dry mouth, constipation, confusion |
| CYP2D6 Inhibitors/Inducers | Potential altered cinnarizine levels/metabolism |
User Reports & Trends (Australian Patient Feedback)
Feedback from Australian forums, ProductReview and pharmacy consultations shows common reasons for use are travel sickness and vertigo.
Many patients report a reduction in travel nausea and improved tolerance of trips after taking cinnarizine.
Common adverse reports include drowsiness and, with prolonged use, worsening tremor or stiffness in some individuals.
Price sensitivity is common and many users choose OTC alternatives such as hyoscine or meclizine where available.
Rural customers often report difficulty sourcing non‑PBS products and sometimes use online suppliers or GP telehealth scripts.
- Patient‑Reported Benefits:
- Reduced motion sickness symptoms.
- Improved vertigo control for some patients.
- Patient‑Reported Harms:
- Drowsiness and sedation.
- Occasional worsening of tremor or stiffness with long‑term use.
| Measure | Satisfaction | Side Effects Reported |
|---|---|---|
| Motion Sickness Relief | Generally Positive | Drowsiness |
| Chronic Vertigo | Mixed | Tremor/Stiffness (long term) |
Clinicians should treat anecdotal reports as signals for assessment and document adverse events via the TGA adverse event reporting system.
Access & Purchase Options
National Chains (Chemist Warehouse, Priceline, TerryWhite)
Because Stugeron is not on the public formulary in Australia, availability at major chains varies between stores and over time.
Some chains may stock imported cinnarizine products or recommend locally approved antiemetics as substitutes.
Always call ahead to confirm stock and ask for ARTG status, batch number and expiry when purchasing imported brands.
- Pharmacy Enquiry Checklist:
- Product name and strength.
- ARTG status or import documentation.
- Batch number and expiry date.
Online Pharmacies And Telehealth E‑Prescriptions
Online Australian pharmacies and telehealth services can prescribe or recommend alternatives and arrange local supply.
Ensure any imported medicine comes with full product information, batch details and a reliable supplier.
For rural patients a telehealth script sent to a local pharmacy often provides the safest route to obtain treatment.
In our online pharmacy, stugeron is available without a prescription, with discreet delivery to Australia in 9-21 days.
Verify pharmacist credentials, ARTG registration where applicable and request product leaflets for counselling.
Mechanism & Pharmacology
Simplified Explanation
Cinnarizine is a calcium channel blocker acting on vestibular hair cells and cerebral blood vessels to reduce vestibular sensitivity.
It likely improves microcirculation and reduces the central perception of dizziness and nausea.
The ATC classification N07CA02 places it among other nervous system drugs for vestibular disorders.
- Glossary:
- ATC N07CA02: Nervous system drugs, calcium channel blockers for vestibular disorders.
- Vestibular Hair Cells: Inner ear cells that detect motion and balance.
For visual content consider a simple diagram showing inner ear, brainstem and symptomatic relief pathways for a blog visual.
Clinical Terms
Onset after an oral dose is usually within 30–120 minutes depending on formulation and food intake.
Half‑life and exposure are influenced by hepatic metabolism, notably CYP2D6 pathways.
Impaired liver function increases systemic exposure and side‑effect risk, so dose reduction or alternatives are recommended in severe hepatic disease.
Sustained‑release forms, where available, may have delayed onset and prolonged effects including sedation.
Indications & Off‑Label Uses
Approved Indications By TGA
The TGA status for cinnarizine/Stugeron is variable and the provided data shows it is not registered in the Australian public formulary.
Internationally cinnarizine is used for motion sickness, vertigo and certain circulatory vestibular disorders.
In Australia clinicians commonly use TGA‑approved antiemetics and vestibular medicines instead of cinnarizine where ARTG status is unclear.
Off‑Label Uses In Australian Clinical Practice
Off‑label uses reported include chronic vestibulopathy and migraine‑related vertigo or cerebral circulatory symptoms.
Off‑label prescribing should be accompanied by informed consent, documented rationale and a clear monitoring plan because of extrapyramidal and sedative risks.
- Off‑Label Documentation Checklist:
- Document clinical rationale and expected benefit.
- Obtain and file informed consent from the patient.
- Schedule regular review for efficacy and adverse effects, especially movement symptoms.
Key Clinical Findings (Australian And International Studies 2022–2026)
Historical RCTs and observational studies support cinnarizine’s efficacy for motion sickness and some vestibular disorders.
Recent literature from 2022–2026 highlights a lack of large modern trials and advises caution, particularly in older adults.
Systematic reviews show comparable effectiveness to antihistamines for motion sickness but a higher rate of sedation and extrapyramidal reactions.
For Australian practice, clinicians should balance symptomatic benefit against safety, especially where ARTG listings and local guidance are limited.
- Study Types Summarised:
- Randomised controlled trials: show symptom reduction in motion sickness.
- Systematic reviews: comparable efficacy to antihistamines with more sedation.
- Observational safety data: signal higher movement disorder risk in long‑term use.
| Outcome | Benefit | Adverse Events |
|---|---|---|
| Motion Sickness | Effective for many patients | Drowsiness common |
| Chronic Vestibular Disorders | Mixed benefit | Risk of tremor/stiffness long term |
Alternatives Matrix
PBS‑Listed Alternatives Comparison Table
| Medicine | PBS Status | Sedation Risk | Anticholinergic Effects | Pregnancy Suitability | Access |
|---|---|---|---|---|---|
| Meclizine | Varies; often available OTC overseas | Moderate | Low–moderate | Check local guidance | Often easier to source |
| Promethazine | PBS‑listed for some indications | High | Moderate | Generally avoided in pregnancy | Prescription may be required |
| Dimenhydrinate | Available OTC in some countries | Moderate | Moderate | Discuss with GP | Accessible alternative |
| Hyoscine (Scopolamine) | PBS options exist for some forms | Moderate | High (anticholinergic) | Use with caution | Patch form available |
Pros And Cons Checklist
- Meclizine: Pros — available and useful for motion sickness; Cons — sedation, variable PBS status.
- Promethazine: Pros — effective antiemetic; Cons — strong sedation and anticholinergic effects.
- Dimenhydrinate: Pros — good short‑term relief; Cons — anticholinergic side effects.
- Hyoscine: Pros — patch option for motion sickness; Cons — anticholinergic burden not suitable for some patients.
Pharmacist‑led choice should consider travel needs versus chronic vertigo, occupation and comorbidities.
Common Questions (FAQs From Australian Pharmacy Consultations)
Patients commonly ask about safety in pregnancy, children, workplace effects and where to purchase.
- Is it safe in pregnancy? Contraindicated; avoid unless a specialist advises.
- Can children take it? Not recommended under 5 years; 5–12 years use reduced dose (12.5 mg two–three times daily).
- Will it affect my job? Drowsiness can impair driving and heavy machinery operation; assess fitness for duty.
- Where can I get it? Availability in Australia is limited; check ARTG, ask local pharmacy or consider PBS‑listed alternatives.
For detailed questions signpost to GP, pharmacist or the TGA consumer information pages and consider reporting side effects to the TGA.
Price & Access Comparison Table
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Pharmacy / Source | Likely Stock Status | Estimated Price (AUD) | PBS Subsidy | Prescription Required |
|---|---|---|---|---|
| Chemist Warehouse | Variable; may stock imports or suggest alternatives | $15–$40 (estimate) | Not generally PBS‑listed | May be OTC or require script depending on supply |
| Priceline | Variable; call ahead | $15–$45 (estimate) | Not generally PBS‑listed | Variable |
| TerryWhite | May source or recommend alternatives | $15–$50 (estimate) | Not generally PBS‑listed | Variable |
| Online Aussie Pharmacies / Authorised Importers | Often available; check supplier credentials | $20–$60 (estimate incl. shipping) | Not PBS | Depends on product and import rules |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Order ahead for rural patients and use telehealth scripts when possible.
- Ask the pharmacist to confirm ARTG, batch and expiry for imported stock.
- Tablets do not require cold‑chain; verify storage during shipping.
Registration & Regulation
TGA Approval
Cinnarizine (Stugeron) is widely used internationally but the provided data states “Australia — Not registered in public formulary”.
Clinicians and pharmacists should verify ARTG registration before supply.
If importing for personal use follow the TGA personal importation scheme rules and document patient consent.
- Regulatory Checks:
- ARTG listing verification.
- Check PBS for subsidy status.
- Review TGA safety alerts before supply.
PBS Subsidy Details
Cinnarizine/Stugeron is not typically PBS‑listed, so patients will likely self‑fund if they obtain this medicine in Australia.
Discuss therapeutically equivalent PBS medicines with patients to reduce out‑of‑pocket costs.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store tablets at room temperature in a cool, dry place away from direct sunlight and moisture.
In hot or humid Australian regions, keep medicines in an air‑conditioned area or insulated container and avoid bathrooms.
Keep all medicines out of reach of children and in original packaging where possible.
- Home Storage Checklist:
- Ideal temperature range: room temperature (do not refrigerate).
- Avoid high humidity and direct sun.
- Return unused medicines to a pharmacy for disposal.
Cold‑Chain Handling For Pharmacies
No refrigeration is required for standard cinnarizine tablets.
Pharmacies should store stock in labelled, secure medicine shelves and keep batch records for imported consignments.
Check certificates and expiry dates on imported stock and quarantine any suspicious consignments and report concerns to the TGA.
Guidelines For Proper Use (Australian Pharmacist Counselling Style)
Australian Pharmacist Counselling Points
Confirm indication — motion sickness versus vertigo — before recommending cinnarizine.
Ask specifically about Parkinson’s disease, pregnancy, liver disease, current CNS medicines, alcohol use and driving or shiftwork.
Explain dosing, likely side‑effects such as drowsiness and signs of extrapyramidal reactions and advise what to do if these occur.
Provide written patient information and record counselling in the patient file.
- Counselling Steps Checklist:
- Confirm indication and contraindications.
- Explain dosing and missed dose rules.
- Advise about driving and alcohol.
- Arrange follow up for chronic use.
Patient Advice From PBS And National Health Authorities
Direct patients to the TGA consumer medicines information for official guidance and ask them to see a GP for complex cases.
Encourage reporting adverse effects to the TGA and returning unused medicines to the pharmacy for safe disposal.
Promote shared decision‑making and regular review, especially when therapy extends beyond short‑term travel use.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 9-14 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 14-21 days |
| Sunshine Coast | Queensland | 14-21 days |
| Geelong | Victoria | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Cairns | Queensland | 14-21 days |